Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.
Fiche publication
Date publication
mars 2018
Journal
Blood
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
Tous les auteurs :
Cottereau AS, Versari A, Luminari S, Dupuis J, Chartier L, Casasnovas RO, Berriolo-Riedinger A, Menga M, Haioun C, Tilly H, Tarantino V, Federico M, Salles G, Trotman J, Meignan M
Lien Pubmed
Résumé
Both total metabolic tumor volume (TMTV), computed on baseline PET, and end of induction PET (EOI PET) are imaging biomarkers showing promise for early risk stratification in patients with high tumor burden follicular lymphoma. A model was built incorporating these two factors in 159 patients from three prospective trials. Median follow up was 64 months. High TMTV (>510cm) and positive EOI PET were independent, significant risk factors for progression. Their combination stratified the population into three risk groups: patients with no risk factors (n = 102;64%) had a 5-year PFS of 67%, versus 33% (HR = 2.9 95%CI (1.8-4.9)) for patients with one (n = 44;27%) and only 23% (HR = 4.6 95%CI (2.3-9.2)) for patients with both risk factors (n = 13;8%); 2-year PFS was respectively 90% versus 61% (HR=4.8 95%CI(2.2-10.4)) and 46% (HR=8.1 95%CI(3.1-21.3)). This model enhances the prognostic value of PET staging and response assessment, identifying a subset of patients with a very high risk of progression and early treatment failure at 2 years.
Référence
Blood. 2018 Mar 20;: